In addition, in patients with non‐small cell lung cancer or urothelial cancer receiving durvalumab monotherapy, elevated PD‐L1 expression and interferon (IFN)‐γ scores in baseline tumor biopsy samples were associated with higher overall reaponse rate (ORR) or improved survival.20, 21. This evidence concerns the gene IFNG and neoplasm.